Medigene AG Market Cap ($1.97 Million)
Market Cap & Net Worth: Medigene AG (MDG1)
Medigene AG market cap. Medigene AG (XETRA:MDG1) has a market capitalization of $1.97 Million (€1.68 Million) as of November 4, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #30065 globally and #2605 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medigene AG's stock price €0.13 by its total outstanding shares 14737600 (14.74 Million). Also see MDG1 cash generation efficiency for how efficiently the company converts equity into cash flow.
Medigene AG Market Cap History (2015–2025)
Medigene AG market cap history from 2015 to 2025. Data shows change from $284.66 Million to $2.30 Million (-37.01% CAGR). Check latest Medigene AG stock price today for real-time trading data and today's change.
Medigene AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medigene AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MDG1 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
8.27x
Medigene AG's market cap is 8.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $284.66 Million | $6.81 Million | -$13.00 Million | 41.81x | N/A |
| 2016 | $389.41 Million | $9.75 Million | -$9.49 Million | 39.94x | N/A |
| 2017 | $416.57 Million | $11.38 Million | -$13.57 Million | 36.62x | N/A |
| 2018 | $241.50 Million | $7.75 Million | -$17.05 Million | 31.14x | N/A |
| 2019 | $130.89 Million | $10.63 Million | -$19.96 Million | 12.31x | N/A |
| 2020 | $115.19 Million | $8.75 Million | -$28.88 Million | 13.17x | N/A |
| 2021 | $93.75 Million | $10.46 Million | -$9.98 Million | 8.96x | N/A |
| 2022 | $66.10 Million | $31.25 Million | -$8.33 Million | 2.12x | N/A |
| 2023 | $49.90 Million | $6.03 Million | -$16.18 Million | 8.27x | N/A |
Competitor Companies of MDG1 by Market Capitalization
Companies near Medigene AG in the global market cap rankings as of November 4, 2026. Also see Medigene AG asset portfolio for a full breakdown of the balance sheet.
Key companies related to Medigene AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Medigene AG (2015–2025)
Market capitalization of Medigene AG from 2015 to today. Between 2015 and today, Medigene AG's market cap moved from $284.66 Million to $ 2.30 Million, with a yearly change of -37.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €2.30 Million | -87.04% |
| 2024 | €17.75 Million | -64.44% |
| 2023 | €49.90 Million | -24.50% |
| 2022 | €66.10 Million | -29.49% |
| 2021 | €93.75 Million | -18.61% |
| 2020 | €115.19 Million | -12.00% |
| 2019 | €130.89 Million | -45.80% |
| 2018 | €241.50 Million | -42.03% |
| 2017 | €416.57 Million | +6.97% |
| 2016 | €389.41 Million | +36.80% |
| 2015 | €284.66 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 28th, 2026 the market cap of Medigene AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.97 Million USD |
| MoneyControl | $1.97 Million USD |
| MarketWatch | $1.97 Million USD |
| marketcap.company | $1.97 Million USD |
| Reuters | $1.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more